Cost Burdens on Patients Older than 66 with Oral Cavity, Pharyngeal Cancers
the Cancer Therapy Advisor take:
Several factors including demographics, comorbidities, and treatment selection are associated with the burdensome Medicare cost of oral and pharyngeal cancer in older patients, according to an article published online in the journal JAMA Otolaryngology—Head & Neck Surgery.
Participants in this study included patients 66 and older with newly diagnosed oral cavity (n = 6,724) and pharyngeal (n = 3,987) cancers between January 1, 1995, and December 31, 2005.
Results showed demographics, comorbidities, and treatment types were all associated with a significant cost increase. African Americans accumulated $11,450 (95% CI: $1,320, $22,299) more in costs for oral cavity cancer and $25,093 (95% CI: $14,917 - $ 34,985) more in costs for pharyngeal cancer.
The mean 5-year cumulative costs for patients with the presence of one or two comorbidities and oral cavity cancer increased by $13,342 (95% CI: $6248, $19,186) and $14,139 (95% CI: $6,009, $22,217) for those with pharyngeal cancer. With the presence of three or more comorbidities, the mean 5-year cumulative costs for patients with oral cavity cancer increased by $22,196 (95% CI: $15,319, $28,614), while an increase of $27,799 (95% CI: $19,139, $36,702) was observed for patients with pharyngeal cancer.
Patients with oral cavity and pharyngeal cancers who received chemotherapy accrued a mean of $26,919 (95% CI: $18,309, $35,056) and $37,407 (95% CI: $29,971, $44,644) more in Medicare costs by 5 years.
Several factors associated with the burdensome Medicare cost of oral and pharyngeal cancer in older patients.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Ginkgo Biloba and Cancer
- Initial Therapy at Academic Centers Linked to Prolonged Overall Survival in NSCLC
- Affordable Care Act Linked to Lower Rates of Cancer Diagnosis Among Uninsured
- FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma, Questions Remain About Cost and Toxicity
- PAK Inhibition Could Abrogate MAPK Inhibitor Resistance in BRAF-mutant Melanoma
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC